Health News Releases

  • Today October 19
September 14, 17:23
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54602408&newsitemid=20260914748441&lan=en-US&anchor=TSE%3A4
September 11, 13:30
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Chugai Pharmaceutical Co., Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.chugai-pharm.co.jp%2Fenglish%2Findex.html&esheet=54600887&newsitemid=20260909923883&lan=en-US&anc
September 10, 15:25
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nejm.org%2Fstoken%2Fdefault%2Bdomain%2FREPRINTS_375
September 10, 09:23
Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 (“H1 2026”). P
September 04, 11:40
Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. F
September 03, 17:50
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd.
September 02, 11:45
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines (https://beonemedicines.com/), Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access
September 02, 11:00
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedul
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com (https://www.angelaligner.com/)), the second largest clear aligner supplier by revenue, announced today that its reven
September 02, 10:30
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse
September 02, 10:00
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) o
September 01, 10:40
Laboratory Modernization Strengthens QPS Holdings, LLC’s Long-Term Commitment to Elemental Bioanalysis
QPS Holdings, LLC (QPS) today announced a significant renewal of its elemental bioanalysis infrastructure through the acquisition of two PerkinElmer NexION® 2200 inductively coupled plasma mass spectr
MIMRYLO Logo
August 30, 14:12
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54593875&newsitemid=20260824773270&lan=en-US&anchor=TSE%3A4
August 27, 15:50
NIPPON KINZOKU Establishes Mass Production of Ultra-Thin and Narrow Stainless Steel for Insulin Needles
NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) is pleased to announce the commencement of mass production for its “Ultra-thin and narrow-width sta
August 27, 09:35
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54594386&newsitemid=20260825943679&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
블라블라
August 24, 16:00
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54590997&newsitemid=20260818063761&lan=en-US&anc
August 24, 11:00
Novotech Strengthens Presence in Japan with Opening of Tokyo Office
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment bui
August 19, 17:40
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
August 12, 14:01
Align Technology Prevails in China Patent Infringement Action Against Angelalign
Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan
August 11, 10:50
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54586664&newsitemid=20260810801799&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=
August 10, 10:50
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Co
Eight Ophthalmologists at BGN Eye Clinic Jamsil Specializing in SMILE LASIK, LASEK, ICL, Presbyopia
August 10, 08:00
Is a Lower SMILE LASIK Price Really the Best Choice? Three Things to Consider Beyond Cost
Dr. Se-Kwang Park, Chief Ophthalmologist at BGN Eye Clinic Jamsil, has advised patients on what to consider when selecting a clinic for SMILE LASIK surgery. For many people considering vision corre
August 07, 11:20
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54583421&newsitemid=20260805570642&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
August 06, 10:43
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/stock-information/)) announced that the U.S. Food and Drug Administration (FDA) approved (https://www.fda.gov/news-events/press-announcement
August 05, 14:30
WHOOP Expands Commitment to Women’s Health by Including One-Year Subscription of Natural Cycles° App in Membership
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2F%3Fsrsltid%3DAfmBOoqrUNUmqB7UR9PSkcUqTlIlQZFv-cFnFEHe-4KarW-TDybGdsAu&esheet=54582456&newsitemid=20260804399367
August 05, 11:50
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available
25 per page50 per page75 per page100 per page